SCHEMBL1409347

SCHEMBL1409347

CCOC(=O)/C=C/c1ccc(-c2cccc(OC)c2C(F)(F)F)o1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.41
KDM4E B2RXH2 6/20 0.40
MAPT P10636 5/20 0.40
FDPS P14324 1/20 0.39
ALDH1A1 P00352 7/20 0.39
LMNA P02545 3/20 0.38
TDP1 Q9NUW8 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
CTDSP1 Q9GZU7 1/20 0.38
PDE7A Q13946 1/20 0.38
PDE3A Q14432 1/20 0.38
HPGD P15428 4/20 0.38
MEN1 O00255 2/20 0.38
PKM P14618 2/20 0.38
RECQL P46063 2/20 0.38
KMT2A Q03164 2/20 0.38
GLA P06280 1/20 0.38
GAA P10253 1/20 0.38
MDM2 Q00987 1/20 0.37
CYP3A4 P08684 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14300744 0.86 KDM4E (0.53) KDM4EMAPTALDH1A1LMNATDP1
SCHEMBL14300745 0.86 KDM4E (0.53) KDM4EMAPTALDH1A1LMNATDP1
SCHEMBL1410226 0.83 PDE7A (0.44) MAOBKDM4EMAPTALDH1A1LMNA
SCHEMBL1410156 0.81 TDP1 (0.40) KDM4EMAPTALDH1A1LMNATDP1
SCHEMBL1409350 0.78 MAPT (0.40) KDM4EMAPTALDH1A1LMNATDP1
SCHEMBL1410093 0.78 MAPT (0.38) KDM4EMAPTALDH1A1LMNATDP1
SCHEMBL1409527 0.77 FDPS (0.44) MAOBKDM4EMAPTFDPSALDH1A1
SCHEMBL1410150 0.75 KDM4E (0.69) KDM4EMAPTALDH1A1LMNAHPGD
SCHEMBL1410410 0.73 ALDH1A1 (0.54) KDM4EMAPTALDH1A1LMNAHPGD
SCHEMBL1409349 0.73 ALDH1A1 (0.47) KDM4EMAPTALDH1A1LMNATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110251187-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110251187-A1 HETEROCYCLIC COMPOUND NES, BMI1, DOT1L MAOB 1180/4885KDM4E 641/4885MAPT 3305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.